Central Effects of Beta-Blockers May Be Due to Nitric Oxide and Hydrogen Peroxide Release Independently of Their Ability to Cross the Blood-Brain Barrier.
beta-blockers
blood-brain barrier
infantile hemangioma
propranolol
reactive oxygen species
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
11
2018
accepted:
15
01
2019
entrez:
16
2
2019
pubmed:
16
2
2019
medline:
16
2
2019
Statut:
epublish
Résumé
Propranolol is the first-line treatment for infants suffering from infantile hemangioma. Recently, some authors raised the question of potential neurologic side effects of propranolol due to its lipophilic nature and thus its ability to passively cross the blood-brain barrier (BBB) and accumulate into the brain. Hydrophilic beta-blockers, such as atenolol and nadolol, where therefore introduced in clinical practice. In addition to their classical mode of action in the brain, circulating factors may modulate the release of reactive oxygen/nitrogen species (ROS/RNS) from endothelial cells that compose the BBB without entering the brain. Due to their high capacity to diffuse across membranes, ROS/RNS can reach neurons and modify their activity. The aim of this study was to investigate other mechanisms of actions in which these molecules may display a central effect without actually crossing the BBB. We first performed an oral treatment in mice to measure the accumulation of propranolol, atenolol and nadolol in different brain regions
Identifiants
pubmed: 30766473
doi: 10.3389/fnins.2019.00033
pmc: PMC6365417
doi:
Types de publication
Journal Article
Langues
eng
Pagination
33Références
Free Radic Res. 1999 Dec;31(6):577-96
pubmed: 10630682
Endocrinology. 2001 Oct;142(10):4288-94
pubmed: 11564686
Int Rev Cytol. 2005;247:89-164
pubmed: 16344112
Sci Signal. 2009 Apr 28;2(68):re2
pubmed: 19401594
Am J Med Sci. 1990 Apr;299(4):236-44
pubmed: 1969714
J Exp Biol. 2010 Jan 15;213(2):288-94
pubmed: 20038663
Peptides. 2010 Apr;31(4):757-76
pubmed: 20093161
Arch Dermatol. 2010 Jul;146(7):775-8
pubmed: 20644039
Antioxid Redox Signal. 2011 Sep 15;15(6):1477-96
pubmed: 21395477
Trends Endocrinol Metab. 2012 Mar;23(3):142-53
pubmed: 22305519
Br J Dermatol. 2013 Jan;168(1):222-4
pubmed: 22762503
Surg Radiol Anat. 2013 May;35(4):343-9
pubmed: 23247732
Antioxid Redox Signal. 2014 Feb 1;20(4):557-73
pubmed: 23879244
J Plast Reconstr Aesthet Surg. 2013 Dec;66(12):1732-40
pubmed: 24011909
Endocrinology. 2014 Jun;155(6):2166-77
pubmed: 24654785
N Engl J Med. 2015 Feb 19;372(8):735-46
pubmed: 25693013
Heart Rhythm. 2015 Aug;12(8):1815-9
pubmed: 25929701
Br J Dermatol. 2015 Dec;173(6):1562-4
pubmed: 26135132
Pediatr Dermatol. 2015 Sep-Oct;32(5):690-5
pubmed: 26215612
Gut. 2017 Feb;66(2):258-269
pubmed: 26565000
J Am Acad Dermatol. 2016 Jul;75(1):59-63.e1
pubmed: 27021240
Medicine (Baltimore). 2016 Jun;95(24):e3908
pubmed: 27310994
Br J Dermatol. 2017 May;176(5):1400-1402
pubmed: 28112790
J Am Acad Dermatol. 2017 Jul;77(1):105-108
pubmed: 28190620
Pediatr Dermatol. 2017 Sep;34(5):554-558
pubmed: 28804922
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):e117-e119
pubmed: 28921662
FEBS Lett. 2018 Mar;592(5):692-702
pubmed: 29292494
Br J Dermatol. 2018 Jun;178(6):1443-1444
pubmed: 29330846
Mol Metab. 2018 Apr;10:100-108
pubmed: 29428595
Oxid Med Cell Longev. 2018 Mar 27;2018:1501847
pubmed: 29770164
Br J Clin Pharmacol. 1981 Jun;11(6):549-53
pubmed: 6115665
Biochim Biophys Acta. 1998 Mar 12;1380(1):55-63
pubmed: 9545532
Endocrinology. 1999 Feb;140(2):652-9
pubmed: 9927290